SCHEDULE 13D/A: Apeiron Investment Group Reduces Stake in Neuphoria Therapeutics Below 5% Threshold
Beneficial Ownership Change (Schedule 13D Amendment)
Apeiron Investment Group and its affiliates have sold shares of Neuphoria Therapeutics Inc., reducing their beneficial ownership to 4.5% following the company's redomiciliation.
Summary
- Apeiron Investment Group Ltd. and Christian Angermayer, its majority shareholder, reported a decrease in their beneficial ownership of Neuphoria Therapeutics Inc. (formerly Bionomics Limited) Common Stock.
- The filing, Amendment No. 2 to Schedule 13D, indicates that as of January 24, 2025, the reporting persons no longer beneficially own more than 5% of the outstanding Common Stock.
- On January 24, 2025, Apeiron sold 55,414 shares of Common Stock in an open market transaction on the Nasdaq Global Market at an average price of $10.8428 per share.
- Following this sale, Apeiron Investment Group Ltd. and Christian Angermayer beneficially own an aggregate of 72,618 shares, representing 4.5% of the 1,628,659 shares of Common Stock outstanding as of December 31, 2024.
- The change in ownership follows the redomiciliation of Bionomics Limited, an Australian public company, to Neuphoria Therapeutics Inc., a Delaware corporation, which was implemented on December 23, 2024.
- As a result of the redomiciliation, Bionomics Limited became a wholly-owned subsidiary of Neuphoria, and all outstanding Ordinary Shares and ADSs were converted into Neuphoria Common Stock.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to a significant shareholder reducing their stake, which can be perceived as a lack of confidence, although the filing itself is a routine disclosure of ownership change.
Negatives
- A significant shareholder, Apeiron Investment Group, has reduced its stake in Neuphoria Therapeutics Inc. by selling 55,414 shares, which could be perceived negatively by the market as a lack of conviction or a move to reallocate capital.
Future Outlook
The document does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing instead on the change in beneficial ownership.
Industry Context
This filing primarily concerns a change in a significant shareholder's stake following a corporate redomiciliation. It does not provide broader industry context or trends, but the redomiciliation itself suggests a strategic move to a new corporate domicile, potentially for market access or regulatory reasons.
Stakeholder Impact
- Shareholders: The reduction in a significant investor's stake might lead to concerns about the stock's future performance or the company's strategic direction, potentially influencing share price.
Key Dates
| Date | Description |
|---|---|
| 2021-12-30 | Original Schedule 13D filed with the SEC. |
| 2024-12-23 | Effective Date of the redomiciliation of Bionomics Limited to Neuphoria Therapeutics Inc. |
| 2024-12-31 | Date as of which 1,628,659 shares of Common Stock were outstanding. |
| 2025-01-24 | Date of event requiring filing of this statement; Apeiron sold 55,414 shares of Common Stock. |
| 2025-01-28 | Date of signing of the Amendment No. 2 to Schedule 13D. |
Recommendation
holdKeywords
Neuphoria Therapeutics Inc., Apeiron Investment Group, Schedule 13D, Common Stock, Share Sale, Beneficial Ownership, Redomiciliation, Bionomics Limited, Nasdaq Global Market, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.